Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ROS1 fusion ROS1 G2032R |
Therapy | Repotrectinib |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ROS1 fusion ROS1 G2032R | lung non-small cell carcinoma | predicted - sensitive | Repotrectinib | Phase I | Actionable | In a Phase I/II trial (TRIDENT-1), Augtyro (repotrectinib) treatment resulted in a confirmed objective response rate of 59% (10/17) in patients with TKI-pretreated, ROS1 fusion-positive non-small cell lung cancer harboring ROS1 G2032R (PMID: 38197815; NCT03093116). | 38197815 |
PubMed Id | Reference Title | Details |
---|---|---|
(38197815) | Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. | Full reference... |